Cretostimogene Promising for High-Risk, Non-Muscle-Invasive Bladder Cancer

THURSDAY, Aug. 6, 2026-- For patients with high-risk, non-muscle-invasive bladder cancer, the oncolytic immunotherapy cretostimogene grenadenorepvec shows a clinically meaningful antitumor response, according to a study published in the August...